Recent events
Recent events tied to this brand in public sources.
Back to profile95 entries · Page 5 of 5
2020
Schrödinger and AstraZeneca expand collaboration
Schrödinger announced an expanded collaboration with AstraZeneca to further develop a modeling solution for biologicals, building on their existing collaboration in small-molecule drug research.
2020
My Green Lab and AstraZeneca announce laboratory sustainability collaboration
My Green Lab and AstraZeneca announced a collaboration to implement a global-scale green labs program across AstraZeneca research sites. Over the next six months, My Green Lab planned to work with AstraZeneca to certify its R&D labs at the named locations to the My Green Lab global standard for laboratory sustainability.
2020
MiNA Therapeutics and AstraZeneca begin metabolic-disease research collaboration
MiNA Therapeutics announced the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA molecules in metabolic diseases. The companies will conduct in vitro and in vivo studies; AstraZeneca may later negotiate a license to further develop certain molecules.
2019
SK Holdings reaffirms strategic partnership with AstraZeneca
SK Holdings reaffirmed its commitment to its strategic partnership with AstraZeneca, as part of its push to grow its biotech and pharmaceutical sectors.
2019
FDA approves Calquence for chronic lymphocytic leukemia and small lymphocytic lymphoma
AstraZeneca secured US FDA approval for its Calquence (acalabrutinib) to treat adults with chronic lymphocytic leukaemia or small lymphocytic lymphoma.
2019
AstraZeneca and Sun Pharma sign China oncology-products agreement
AstraZeneca and Sun Pharma signed a cooperation agreement under which AstraZeneca will handle the introduction and promotion in China of several Sun Pharma oncology products.
2019
AstraZeneca and Omron announce global strategic partnership
AstraZeneca and Omron announced a long-term global strategic partnership to jointly develop disease-management solutions in respiratory, cardiovascular and metabolic diseases.
2019
AstraZeneca announces an upgraded R&D platform in China
AstraZeneca announced that it would upgrade its existing Shanghai R&D platform to a global R&D center and establish an AI innovation center in Shanghai.
2019
AstraZeneca and CICC announce a China healthcare investment fund
AstraZeneca said it was launching a fund with China International Capital Corporation to invest $1 billion in China's healthcare sector. The agreement was to be signed at the China International Import Expo.
2019
Antengene and AstraZeneca sign global AZD0364 license agreement
Antengene announced a global exclusive license agreement with AstraZeneca to advance clinical development, production and commercialization of AZD0364 worldwide.
2019
AstraZeneca raises annual product sales forecast
AstraZeneca raised its annual product sales forecast to low- to mid-teens percentage growth, from a previous forecast of low double-digit growth.
2019
FDA approves Farxiga for a heart-failure prevention use
The FDA approved AstraZeneca’s drug Farxiga for a new use to reduce the chances of heart-failure hospitalisation in adults with type 2 diabetes and other cardiovascular risks.
2019
AstraZeneca selects PetaGene software for genomics research
PetaGene announced that AstraZeneca selected its PetaSuite software to compress genomics datasets for AstraZeneca’s Centre for Genomics Research.
2019
ImaginAb and three pharmaceutical companies sign collaboration agreement
ImaginAb announced that it signed a multi-party collaboration agreement with AstraZeneca, Pfizer and Takeda to further the clinical development of its CD8 ImmunoPET technology. The collaborators will help guide an ImaginAb-sponsored clinical trial and contribute to post-trial data analysis.
2019
AstraZeneca announces drug discovery collaboration with insitro
AstraZeneca announced that it had entered into a strategic drug discovery collaboration and licensing agreement with insitro.